Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment

[1]  P. Noseworthy,et al.  Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) , 2020, Mayo Clinic Proceedings.

[2]  R. Hoffman,et al.  Toxicokinetics of hydroxychloroquine following a massive overdose. , 2019, The American journal of emergency medicine.

[3]  M. Boutjdir,et al.  Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation , 2018, PloS one.

[4]  D. Yoon,et al.  Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice , 2018, BioMed research international.

[5]  Wei Zhang,et al.  Azithromycin Causes a Novel Proarrhythmic Syndrome , 2017, Circulation: Arrhythmia and Electrophysiology.

[6]  Long Chen,et al.  Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin , 2017, Cardiovascular Toxicology.

[7]  Parag H Mehta,et al.  Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine , 2016, Case reports in cardiology.

[8]  W. Palmer,et al.  Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study , 2016, Drugs - Real World Outcomes.

[9]  Gary R. Mirams,et al.  Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential , 2015, Heart rhythm.

[10]  Assessment of temperature‐induced hERG channel blockade variation by drugs , 2015, Journal of applied toxicology : JAT.

[11]  Sheetal Patel,et al.  Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. , 2013, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[12]  J. Alexander,et al.  Cardiovascular risks with azithromycin and other antibacterial drugs. , 2013, The New England journal of medicine.

[13]  C Michael Stein,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[14]  C. Hsia,et al.  Azithromycin‐Induced Torsade De Pointes , 2007, Pacing and clinical electrophysiology : PACE.

[15]  J. Fisher,et al.  Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors , 2007, Journal of Interventional Cardiac Electrophysiology.

[16]  Chih-Chuan Lin,et al.  Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia , 2006, Clinical toxicology.

[17]  R. Trohman,et al.  Polymorphic Ventricular Tachycardia with a Normal QT Interval Following Azithromycin , 2005, Pacing and clinical electrophysiology : PACE.